Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ferucarbotran→

Ferucarbotran Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
Not available
Drug class
Superparamagnetic iron-oxide nanoparticle MRI contrast agentliver-specific reticuloendothelial contrast medium
Mechanism of action
Carboxydextran-coated superparamagnetic iron oxide nanoparticles are phagocytosed by Kupffer cells in the hepatic reticuloendothelial system. Their strong T2 and T2* relaxivity reduces signal intensity in normal liver parenchyma, increasing contrast between normal liver and lesions with reduced Kupffer-cell uptake.
Indications / reported uses
  • Contrast enhancement for magnetic resonance imaging of focal liver lesions, particularly to improve lesion detection and characterisation in the liver, under product authorisation.

Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC2727962/ · https://pubmed.ncbi.nlm.nih.gov/23256052/ · https://pmc.ncbi.nlm.nih.gov/articles/PMC4611768/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ferucarbotran Environmental Risk Assessment (ERA) (the Ferucarbotran ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.